These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The best models of metabolism. Voit EO Wiley Interdiscip Rev Syst Biol Med; 2017 Nov; 9(6):. PubMed ID: 28544810 [TBL] [Abstract][Full Text] [Related]
44. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Zhang L; Hedjran F; Larson C; Perez GL; Reid T Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035 [TBL] [Abstract][Full Text] [Related]
45. Multiscale modeling of brain dynamics: from single neurons and networks to mathematical tools. Siettos C; Starke J Wiley Interdiscip Rev Syst Biol Med; 2016 Sep; 8(5):438-58. PubMed ID: 27340949 [TBL] [Abstract][Full Text] [Related]
46. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives]. Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343 [TBL] [Abstract][Full Text] [Related]
47. Modeling of oncolytic viruses in a heterogeneous cell population to predict spread into non-cancerous cells. Buntval K; Dobrovolny HM Comput Biol Med; 2023 Oct; 165():107362. PubMed ID: 37633084 [TBL] [Abstract][Full Text] [Related]
48. Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses. Speranza MC; Kasai K; Lawler SE ILAR J; 2016; 57(1):63-72. PubMed ID: 27034396 [TBL] [Abstract][Full Text] [Related]
49. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615 [TBL] [Abstract][Full Text] [Related]
50. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801 [TBL] [Abstract][Full Text] [Related]
51. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Nguyên TL; Abdelbary H; Arguello M; Breitbach C; Leveille S; Diallo JS; Yasmeen A; Bismar TA; Kirn D; Falls T; Snoulten VE; Vanderhyden BC; Werier J; Atkins H; Vähä-Koskela MJ; Stojdl DF; Bell JC; Hiscott J Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14981-6. PubMed ID: 18815361 [TBL] [Abstract][Full Text] [Related]
52. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers. Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815 [TBL] [Abstract][Full Text] [Related]
53. Complex Dynamics of Virus Spread from Low Infection Multiplicities: Implications for the Spread of Oncolytic Viruses. Rodriguez-Brenes IA; Hofacre A; Fan H; Wodarz D PLoS Comput Biol; 2017 Jan; 13(1):e1005241. PubMed ID: 28107341 [TBL] [Abstract][Full Text] [Related]
54. Genome-scale metabolic models applied to human health and disease. Cook DJ; Nielsen J Wiley Interdiscip Rev Syst Biol Med; 2017 Nov; 9(6):. PubMed ID: 28644920 [TBL] [Abstract][Full Text] [Related]
55. Modeling, signaling and cytoskeleton dynamics: integrated modeling-experimental frameworks in cell migration. Sun M; Zaman MH Wiley Interdiscip Rev Syst Biol Med; 2017 Jan; 9(1):. PubMed ID: 27863122 [TBL] [Abstract][Full Text] [Related]
56. Insights into nuclear dynamics using live-cell imaging approaches. Bigley RB; Payumo AY; Alexander JM; Huang GN Wiley Interdiscip Rev Syst Biol Med; 2017 Mar; 9(2):. PubMed ID: 28078793 [TBL] [Abstract][Full Text] [Related]